ANVS
$2.60-0.07 (-2.62%)
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.
Recent News
Annovis (ANVS) Secures Patent Coverage for Both Forms of Buntanetap
Annovis Bio, Inc. (NYSE:ANVS) is one of the best meme stocks. On August 7, Annovis announced that it has finished transferring patents for both the older semi-crystalline and the newer crystalline versions of its drug candidate, buntanetap. These patents will now protect the drug until 2046. The company, which works on drugs for brain-related diseases, […]
We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy
Annovis Bio (ANVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.